Zidovudine myopathy: a distinctive disorder associated with mitochondrial dysfunction

Ann Neurol. 1991 Jun;29(6):606-14. doi: 10.1002/ana.410290607.

Abstract

Muscle biopsy specimens were obtained from 48 human immunodeficiency virus-infected patients suffering from various neuromuscular symptoms. Microscopic examination by conventional and electron microscopy revealed a characteristic structural myopathy associated with mitochondrial changes in 13 patients, all of whom had received long-term zidovudine therapy. The mean cumulative dose they had received (498 +/- 145 gm) was significantly higher than that of the other 14 zidovudine recipients of the study. They suffered from a progressive, usually painful, proximal myopathy with pronounced wasting, normal-to-moderately elevated creatine kinase levels, and a myopathic electromyographic pattern. The condition usually improved after withdrawal of the drug. Assay of mitochondrial enzymes, including succinate-cytochrome c reductase, cytochrome c oxidase, and citrate synthase, showed a decline in respiratory chain capacity. Southern blot analysis of mitochondrial DNA showed no abnormality. It is likely that mitochondrial dysfunction, probably resulting from drug-induced inhibition of the mitochondrial DNA polymerase, is implicated in the pathogenesis of this complication of zidovudine therapy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • DNA Polymerase III / antagonists & inhibitors
  • DNA Replication / drug effects
  • DNA, Mitochondrial / biosynthesis
  • HIV Infections / complications
  • HIV Infections / drug therapy
  • Humans
  • Male
  • Microscopy, Electron
  • Middle Aged
  • Mitochondria / drug effects
  • Mitochondria / enzymology
  • Mitochondria / pathology*
  • Muscles / pathology
  • Muscular Diseases / chemically induced*
  • Muscular Diseases / pathology
  • Oxidative Phosphorylation
  • Zidovudine / adverse effects*
  • Zidovudine / therapeutic use

Substances

  • DNA, Mitochondrial
  • Zidovudine
  • DNA Polymerase III